Gold prices snap 4-day losing streak after Fed rate cut, Trump-Xi meeting
SOUTH SAN FRANCISCO - Quince Therapeutics Inc. (NASDAQ:QNCX), a clinical-stage biotech company with a market capitalization of $111 million that has seen its stock surge 174% over the past year, presented data on patient-reported walking capacity in children with Ataxia-Telangiectasia (A-T) at the 54th Child Neurology Society Annual Meeting, according to a company press release.
The presentation analyzed data from 372 children with A-T from the Global A-T Family Data Platform to understand changes in walking capacity with age. Researchers compared a patient-reported walking scale with walking components of two clinician-rated measures – the International Cooperative Ataxia Rating Scale (ICARS) and Rescored modified ICARS (RmICARS). According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.0, though it continues to burn through cash as it advances its clinical programs.
Results indicated that all three scales tracked age-related loss of ambulation similarly, suggesting the suitability of RmICARS walking capacity components in assessing A-T disease progression.
The findings are relevant to Quince’s ongoing Phase 3 NEAT clinical trial of encapsulated dexamethasone sodium phosphate (eDSP), the company’s lead asset for treating A-T.
A-T is a rare inherited neurodegenerative and immunodeficiency disorder typically diagnosed before age five. Patients often become wheelchair-bound by adolescence and face repeated infections, pulmonary impairment, and malignancies during their teenage years. The median lifespan is approximately 25 to 30 years.
The company estimates there are approximately 4,600 diagnosed A-T patients in the U.S. and about 5,000 patients in the U.K. and EU4 countries. There are currently no approved therapeutic treatments for A-T in any global market.
eDSP utilizes Quince’s proprietary Autologous Intracellular Drug Encapsulation technology, which encapsulates dexamethasone sodium phosphate in a patient’s own red blood cells to potentially provide corticosteroid efficacy while reducing adverse effects. With analyst price targets ranging from $4 to $10 per share and the company’s next earnings report due on November 13, investors can access detailed financial analysis and 12 additional ProTips through InvestingPro’s comprehensive coverage.
In other recent news, Quince Therapeutics has reported several noteworthy developments. The company continues to receive positive support from analysts, with both Citizens and JMP Securities maintaining a Market Outperform rating for Quince Therapeutics, each setting a price target of $8.00. This comes amid the publication of pharmacokinetic data for Quince’s enhanced Delivery Steroid Platform (eDSP), which has been validated in ongoing trials. The eDSP therapy is being evaluated in a Phase 3 trial for Ataxia-Telangiectasia, with promising results published in the Journal of the American Society for Clinical Pharmacology and Therapeutics. In addition, Quince Therapeutics has amended its credit facility with the European Investment Bank, reducing the required minimum cash balance and adjusting interest rates for a specific period. These strategic financial adjustments are aimed at supporting the company’s ongoing research and development efforts. Furthermore, the company’s management has been recognized for its effective execution in advancing the pivotal NEAT trial for eDSP. As Quince Therapeutics progresses with its clinical trials, these developments are significant for investors and stakeholders closely monitoring the company’s trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.